ZyVersa Therapeutics, Inc. (ZVSA)
ZVSA moved a median of -0.42% 30 minutes after news, and -1.98% by the close. How ZVSA actually reacts to news — the realized, point-in-time move the market made, measured across 182 labeled events over the last three years with zero look-ahead.
ZVSA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.10% | 37% | 173 |
| 30-min | -0.42% | 40% | 181 |
| 60-min | -1.65% | 35% | 182 |
| to close | -1.98% | 41% | 182 |
| Middle 50% of ZVSA reactions | -3.00% to +1.88% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 182 |
Half of all ZyVersa Therapeutics, Inc. news events land between -3.00% and +1.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ZVSA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ZVSA's baseline. Nothing else.
Recent ZVSA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K ZyVersa Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +21.05% | |
| Form 8-K ZyVersa Therapeutics, For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.40% | |
| Form 10-Q ZyVersa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.80% | +1.17% | |
| ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +3.80% | +1.17% | |
| Form 10-K ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -6.98% | |
| ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -6.98% | |
| Form 8-K ZyVersa Therapeutics, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.70% | |
| Form 8-K ZyVersa Therapeutics, For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.79% | |
| Form 10-Q ZyVersa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.26% | +3.70% | |
| Form 8-K ZyVersa Therapeutics, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -1.26% | +3.70% | |
| ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.26% | +3.70% | |
| Form NT 10-Q ZyVersa Therapeutics, For: Sep 30 | SEC filing · Form NT | SEC EDGAR | +0.00% | +8.68% | |
| Form 8-K ZyVersa Therapeutics, For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -7.41% | -9.94% | |
| Form 8-K ZyVersa Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.67% | |
| ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes | Press release | GlobeNewswire | +0.00% | +17.43% | |
| ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression | Press release | GlobeNewswire | +5.30% | -1.51% | |
| ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression | Press release | GlobeNewswire | +0.00% | +0.33% | |
| Form 10-Q ZyVersa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.25% | -6.13% | |
| ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones | Press release | GlobeNewswire | -6.25% | -6.13% | |
| Form EFFECT ZyVersa Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.83% | +9.64% | |
| Form S-1/A ZyVersa Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -5.26% | -5.16% | |
| Form 8-K ZyVersa Therapeutics, For: Jul 25 | SEC filing · Form 8-K | SEC EDGAR | -3.19% | -14.72% | |
| ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress | Press release | GlobeNewswire | -9.21% | -10.79% | |
| Form S-1/A ZyVersa Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -9.21% | -10.79% | |
| Form 8-K ZyVersa Therapeutics, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -24.90% | -41.45% | |
| Form 8-K ZyVersa Therapeutics, For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | -2.50% | +1.90% | |
| ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | Press release | GlobeNewswire | -8.83% | -34.27% | |
| ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis | Press release | GlobeNewswire | -6.46% | -0.64% | |
| Form S-1 ZyVersa Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | +7.69% | |
| ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) | Press release | GlobeNewswire | +5.49% | +5.33% | |
| Form 8-K ZyVersa Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | +13.13% | |
| ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200 | Press release | GlobeNewswire | +0.86% | +13.13% | |
| Form 8-K ZyVersa Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +2.90% | -5.48% | |
| Form 8-K ZyVersa Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | +7.41% | |
| ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases | Press release | GlobeNewswire | -3.87% | +2.43% | |
| Form 10-Q ZyVersa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.69% | +0.00% | |
| ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress | Press release | GlobeNewswire | +3.69% | +0.00% | |
| ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update | Press release | GlobeNewswire | -4.16% | +3.19% | |
| ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease | Press release | GlobeNewswire | -6.60% | +7.96% | |
| ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status | Press release | GlobeNewswire | -4.84% | -3.23% | |
| Form ARS ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -4.21% | -1.40% | |
| Form DEF 14A ZyVersa Therapeutics, For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | -4.21% | -1.40% | |
| Form DEFA14A ZyVersa Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -4.21% | -1.40% | |
| Form EFFECT ZyVersa Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +10.48% | -26.54% | |
| ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) | Press release | GlobeNewswire | -1.61% | +104.84% | |
| Form 8-K ZyVersa Therapeutics, For: Apr 04 | SEC filing · Form 8-K | SEC EDGAR | -1.61% | +104.84% | |
| Form PRE 14A ZyVersa Therapeutics, For: Apr 07 | SEC filing · Form PRE | SEC EDGAR | -1.61% | +104.84% | |
| Form S-3 ZyVersa Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.90% | -4.84% | |
| Form 10-K ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -9.40% | -4.40% | |
| ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | -9.40% | -4.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ZVSA section they belong to.
Where else ZVSA is measured.
ZVSA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ZyVersa Therapeutics, Inc.'s median reaction calculated?
Every labeled ZVSA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 182 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of ZVSA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ZVSA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.